Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

November 25, 2019

Study Completion Date

November 25, 2019

Conditions
Triple Negative Breast CancerTNBC - Triple-Negative Breast Cancer
Interventions
DRUG

Paclitaxel

standard weekly paclitaxel in 28-day cycles

DRUG

CB-839

CB-839 administered as oral tablets twice daily (BID)

Trial Locations (25)

10032

Columbia University, New York

15213

Magee Womens Hospital - UPMC, Pittsburgh

19104

University of Pennsylvania, Philadelphia

20007

Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.

20010

Washington Cancer Institute, Washington D.C.

21237

Weinberg Cancer Institute at Franklin Square, Baltimore

29414

Charleston Hematology Oncology Associates, Charleston

29605

Greenville Health System (GHS) Cancer Institute, Greenville

30060

Northwest Georgia Oncology, Marietta

30332

Winship Cancer Institute - Emory University, Atlanta

30607

University Cancer and Blood Center, Athens

33176

University of Miami, Miami

33612

Moffitt Cancer Center and Research Institute, Tampa

35294

University of Alabama at Brimingham, Birmingham

36604

University of South Alabama, Mitchell Cancer Institute, Mobile

38138

West Cancer Center, Germantown

48202

Henry Ford Hospital, Detroit

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

63110

Saint Louis University, St Louis

70121

Ochsner Clinic Foundation, New Orleans

77030

Baylor College of Medicine, Houston

MD Anderson, Houston

98405

Northwest Medical Specialties, PLLC, Tacoma

06511

Yale Cancer Center, New Haven

07601

JTCC at Hackensack UMC, Hackensack

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY